4-(6-benzylamino-pyridazin-3-ylethynyl)-benzaldehyde | 1033705-39-3

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二芳基庚烷
• 英文名称: 4-(6-benzylamino-pyridazin-3-ylethynyl)-benzaldehyde
• 英文别名: 4-[2-[6-(Benzylamino)pyridazin-3-yl]ethynyl]benzaldehyde
• CAS: 1033705-39-3
• 化学式: C₂₀H₁₅N₃O
• 分子量: 313.359
• InChiKey: QGUSHWIEQCDLRW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  54.9
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Pyridazine Derivatives with MCH Antagonistic Activity and Medicaments Comprising These Compounds
  申请人：Lehmann-Lintz Thorsten

  公开号：US20100197908A1

  公开（公告）日：2010-08-05

  The present invention relates to compounds of general formula I wherein the groups and radicals B, W, X, Y, Z, R 1 , R 2 , have the meanings given in claim 1 . Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.

  本发明涉及一般式I的化合物，其中基团和基团B、W、X、Y、Z、R1、R2的含义如权利要求书1所述。此外，本发明还涉及含有本发明中至少一种化合物的制药组合物。由于其MCH受体拮抗活性，本发明中的制药组合物适用于治疗代谢性疾病和/或饮食障碍，特别是肥胖症、暴食症、厌食症、暴食症和糖尿病。
• NEW PYRIDAZINE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2102171A1

  公开（公告）日：2009-09-23
• [EN] NEW PYRIDAZINE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS<br/>[FR] NOUVEAUX DÉRIVÉS PYRIDAZINES À ACTIVITÉ ANTAGONISTE DU RÉCEPTEUR MCH ET MÉDICAMENTS COMPRENANT CES COMPOSÉS
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2008071646A1

  公开（公告）日：2008-06-19

  [EN] The present invention relates to compounds of general formula I wherein the groups and radicals B, W, X, Y, Z, R¹, R², have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one compound according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.
  [FR] La présente invention concerne des composés de formule générale (I) dans laquelle les groupes et radicaux B, W, X, Y, Z, R¹, R², sont tels que définis dans la revendication 1. L'invention concerne également des compositions pharmaceutiques contenant au moins un composé selon l'invention. Grâce à leur activité antagoniste du récepteur MCH, les compositions pharmaceutiques selon l'invention sont aptes au traitement de troubles métaboliques et/ou de troubles de l'alimentation, notamment l'obésité, la boulimie, l'anorexie, l'hyperphagie et le diabète.